



## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX	
Name of listed issuer:	Oceania Healthcare Limited
Date this disclosure made:	20 August 2020
Date of last disclosure:	24 March 2020

#### Director or senior manager giving disclosure

Full name(s):	Gregory Tomlinson
Name of listed issuer:	Oceania Healthcare Limited
Name of related body corporate (if applicable):	N/A
Position held in listed issuer:	Director

#### Summary of acquisition or disposal of relevant interest (excluding derivatives)

Class of affected quoted financial products:	Ordinary shares
Nature of the affected relevant interest(s):	Gregory Tomlinson has the power to control the exercise of a right to vote attached to the product and the power to control the acquisition and disposal of the product.
<b>For that relevant interest -</b>	
Number held in class before acquisition or disposal:	15,223,352
Number held in class after acquisition or disposal:	16,386,263
Current registered holder(s):	New share issues
Registered holder(s) once transfers are registered:	Tomlinson Group Investments Limited

#### Summary of acquisition or disposal of relevant interest (excluding derivatives)

Class of affected quoted financial products:	Ordinary shares
Nature of the affected relevant interest(s):	Harrogate Trustee Limited or its directors are accustomed to act in accordance with Gregory Tomlinson's wishes in relation to a relevant interest held by Harrogate Trustee Limited.
<b>For that relevant interest -</b>	
Number held in class before acquisition or disposal:	3,634,980

Number held in class after acquisition or disposal:	3,678,995
Current registered holder(s):	New share issue
Registered holder(s) once transfers are registered:	Harrogate Trustee Limited

**Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)**

Type of affected derivative:	N/A
Class of underlying financial products:	N/A

**Details of affected derivative -**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative (if any):	N/A
The price specified in the terms of the derivative (if any):	N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	N/A

*For that derivative: -*

Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	N/A

**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:	1
---	---

**Details of transactions requiring disclosure -**

Date of transaction:	13 August 2020
Nature of transaction:	Issue of shares to Tomlinson Group Investments Limited pursuant to a sub-underwriting arrangement with Macquarie Securities (NZ) Limited
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:	\$1,030,049.36
Number of financial products to which the transaction related:	1,039,404

*If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details -*

Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	N/A
Date of the prior written clearance (if any):	N/A

**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:	1
---	---

**Details of transactions requiring disclosure -**

Date of transaction:	17 August 2020
Nature of transaction:	Acquisition of 123,507 ordinary shares in Oceania Healthcare Limited by Tomlinson Group Investments Limited in accordance with the Dividend Reinvestment Plan 2019
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:	\$122,395.75
Number of financial products to which the transaction related:	123,507

*If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details -*

Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	N/A
Date of the prior written clearance (if any):	N/A

**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:	1
---	---

**Details of transactions requiring disclosure -**

Date of transaction:	17 August 2020
Nature of transaction:	Acquisition of 44,015 ordinary shares in Oceania Healthcare Limited by Tomlinson Group Investments Limited in

	accordance with the Dividend Reinvestment Plan 2019
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:	\$43,619.76
Number of financial products to which the transaction related:	44,015

*If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details -*

Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	N/A
Date of the prior written clearance (if any):	N/A

**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:	N/A
Nature of relevant interest:	N/A

*For that relevant interest -*

Number held in class:	N/A
Current registered holder(s):	N/A

*For a derivative relevant interest -*

Type of derivative:	N/A
---------------------	-----

**Details of derivative -**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative (if any):	N/A
The price's specified terms (if any):	N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	N/A

*For that derivative relevant interest:*

Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	N/A

---

**Certification**

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:


Date of signature:

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:



20 August 2020
Anna Thorburn General Counsel & Company Secretary